Mesoblast reaches settlement in class action over COVID-19 treatment

Class Actions 2024-09-09 12:57 pm By Christine Caulfield

Mesoblast has agreed to settle a shareholder class action centred on statements to the market about its Remestemcel-L treatment, resolving claims it misrepresented the efficacy of the therapy for COVID-19 patients.